David L Scott, Andrew Cope. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Anti-Inflammatory Agents/economicsAnti-Inflammatory Agents/therapeutic useAntibodies, Monoclonal/economicsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedArthritis, Rheumatoid/drug therapyArthritis, Rheumatoid/immunologyCertolizumab PegolCost-Benefit AnalysisHumansImmunoglobulin Fab Fragments/economicsImmunoglobulin Fab Fragments/therapeutic usePatient SelectionPolyethylene Glycols/economicsPolyethylene Glycols/therapeutic useRandomized Controlled Trials as TopicTreatment OutcomeTumor Necrosis Factor-alpha/antagonists & inhibitorsTumor Necrosis Factor-alpha/economics
Substances: See more » Anti-Inflammatory AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedImmunoglobulin Fab FragmentsTumor Necrosis Factor-alphaPolyethylene GlycolsgolimumabCertolizumab Pegol
Year: 2009 PMID: 19435722 DOI: 10.1136/ard.2008.105940
Source DB: PubMed Journal: Ann Rheum Dis ISSN: 0003-4967 Impact factor: 19.103